A Phase 2 Single-arm, Open-label Study of Single-agent Brentuximab Vedotin for Front-line Therapy of Hodgkin
Lymphoma (HL) in Adults Age 60 and Above, NCT01716806
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
This is an open-label, multicenter, phase 2 clinical trial designed to evaluate the efficacy and safety of brentuximab vedotin as a single-agent (Part A) and in combination with dacarbazine (Part B) in front-line therapy of HL in adults age 60 and above.
MORE DETAILS ON THIS LYMPOHOMA TRIAL
11282 / SGN35-015 / NCT01716806 / Re-Open (Part D) 2-9-2017